All In Biotech

Drug Trial Radar · NCT05047523

Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease

A Multicenter, Randomized, Controlled, Open-label, Rater-blinded Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease

Last checked: Nov 20, 2026Latest source record: Oct 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

40

Actual

Start

Sep 13, 2021

Primary completion

Jun 26, 2023

Study completion Jun 26, 2023

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Sep 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics of ALXN1840 versus standard of care in pediatric participants with Wilson disease (WD).

Conditions

  • Wilson Disease

Interventions

  • ALXN1840Drug

    Administered as an oral tablet.

  • Standard of CareDrug

    Depending on the site/region, participants randomized to receive Standard of Care treatment will receive trientine, penicillamine, zinc, or a combination of these medicines, administered according to standard regimens.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline to Week 48 in Non-ceruloplasmin-bound Copper in PlasmaTime frame: Baseline, Week 48

Locations

20 sites in 7 countries. Site status is shown where the registry gives one.

  • Research Site

    Parkville, Australia

  • Research Site

    South Brisbane, Australia

  • Research Site

    Lille, France

  • Research Site

    Toulouse, France

  • Research Site

    Hanover, Germany

  • Research Site

    Tübingen, Germany

  • Research Site

    Kumamoto, Japan

  • Research Site

    Kurume-shi, Japan

  • Research Site

    Meguro-ku, Japan

  • Research Site

    Sapporo, Japan

  • Research Site

    Warsaw, Poland

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Barcelona, Spain

  • Research Site

    Esplugues de Llobregat, Spain

  • Research Site

    Las Palmas de Gran Canaria, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Málaga, Spain

  • Research Site

    Pamplona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.